Figure 2.

Therapeutics for HHV-6B. Intensity of color represents degree of evidence for use of each therapy, where darker color indicates more evidence. No treatments have an approval for HHV-6 except for foscarnet in Japan. Foscarnet and ganciclovir are first-line treatments, while cidofovir and combination treatment are reserved for salvage therapy. Virus-specific T cells and intravenous brincidofovir are investigational and not commercially available. Bid: twice per day; CNS: central nervous system; IV: intravenous.